ANKRD7 Inhibitors
ANKRD7 inhibitors represent a distinct class of chemical compounds designed to specifically downregulate the function of the ANKRD7 protein. ANKRD7, an abbreviation for Ankyrin Repeat Domain 7, is a protein that plays a role in various cellular processes, including intracellular signaling cascades. Inhibitors targeting ANKRD7 are meticulously crafted to interfere with its activity at a molecular level. These compounds typically function by binding directly to the protein or by altering the biochemical pathways that regulate ANKRD7's expression or activity. The precision with which these inhibitors are designed ensures that they impact the protein's function without affecting the broader cellular systems, thereby enabling a targeted approach to modulate ANKRD7's activity.
The molecular action of ANKRD7 inhibitors is complex and multi-faceted. These compounds can inhibit the protein's activity through a variety of mechanisms, such as preventing the protein from adopting its active conformation, obstructing its interaction with other cellular components that are vital for its function, or by impeding the pathways that lead to its activation. Each inhibitor is characterized by its unique mode of action, which is a result of its chemical structure and the specific binding affinity it exhibits towards ANKRD7 or the components of its regulatory pathways. The design of these inhibitors is grounded in comprehensive research that delineates the intricate details of the protein's role within the cell and the signaling networks it influences. By inhibiting ANKRD7, these compounds can effectively reduce the protein's influence on these networks, leading to a decrease in its functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR (mammalian target of rapamycin). mTOR is a downstream effector in the PI3K/AKT pathway, which could be involved in the regulation of ANKRD7 protein stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the activation of AKT, leading to reduced phosphorylation and potential degradation of ANKRD7 through the PI3K/AKT pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the enzyme, which can lead to decreased AKT activity. This may result in lower ANKRD7 expression or activity, given that AKT can regulate protein stability. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which prevents the activation of ERK, a downstream kinase in the MAPK pathway. ERK has been implicated in the regulation of various proteins, potentially including ANKRD7. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK could affect the phosphorylation state and function of downstream proteins, which may affect ANKRD7's role in cellular stress responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which might modulate the activity of transcription factors that regulate ANKRD7 expression, leading to decreased protein levels. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. By preventing proteasomal degradation, it can lead to accumulation of ubiquitinated proteins, potentially affecting the degradation pathway of ANKRD7, if it is regulated by ubiquitination. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein biosynthesis by interfering with the translocation step in protein synthesis, which could reduce overall levels of ANKRD7 if it has a short half-life. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disturb the degradation pathway of proteins. If ANKRD7 turnover is regulated by the ubiquitin-proteasome system, its levels and activity might be indirectly inhibited by bortezomib. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA is an inhibitor of histone deacetylases (HDAC). By altering the acetylation state of histones, it can change the expression patterns of genes, possibly including those that regulate ANKRD7. | ||||||